Zentalis Pharmaceuticals shares fall 1.45% intraday after announcing inducement grants to new employees.

Zentalis Pharmaceuticals, Inc. declined 1.45% in intraday trading, with the company announcing inducement grants to newly hired employees. The company is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting fundamental biological pathways of cancers. The company's lead product candidate includes azenosertib (ZN-c3), a WEE1 inhibitor for advanced solid tumors and hematological malignancies.